The Recall Desk

Archive

April 2015 recalls

1,319 recalls were announced in April 2015.

What the numbers show

Critical
109
Severe
527
High
388
Moderate
278
Low
17

Of the 1,319 recalls this month scored against our rubric, 8% are Critical, 40% are Severe.

201–300 of 1319

  • SevereFDA (Drugs)·D-774-2015·2015-04-29

    Attix Pharmaceuticals Recalls Meclofenoxate HCl Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Meclofenoxate HCl active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Meclofenoxate HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-955-2015·2015-04-29

    Attix Pharmaceuticals Recalls Voriconazole Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Voriconazole active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Voriconazole active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-781-2015·2015-04-29

    Attix Pharmaceuticals Recalls Metformin HCl Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Metformin HCl active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Metformin HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-566-2015·2015-04-29

    Attix Pharmaceuticals Recalls Cefadroxil Monohydrate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Cefadroxil Monohydrate active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Cefadroxil Monohydrate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-523-2015·2015-04-29

    Attix Pharmaceuticals Recalls Aprepitant API Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling all lots of Aprepitant active pharmaceutical ingredient distributed between January 2012 and February 2015 due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Aprepitant active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-549-2015·2015-04-29

    Attix Pharmaceuticals Recalls Bromocriptine Mesylate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Bromocriptine Mesylate active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Bromocriptine Mesylate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-813-2015·2015-04-29

    Attix Pharmaceuticals Recalls Naproxen Sodium Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Naproxen Sodium active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Naproxen Sodium active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-692-2015·2015-04-29

    Attix Pharmaceuticals Recalls Formoterol Fumarate Dihydrate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Formoterol Fumarate Dihydrate active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Formoterol Fumarate Dihydrate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-756-2015·2015-04-29

    Attix Pharmaceuticals Recalls Levocetirizine HCl Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Levocetirizine HCl active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Levocetirizine HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-878-2015·2015-04-29

    Retinoic Acid Recalled for Potential Penicillin Cross Contamination

    Attix Pharmaceuticals is recalling Retinoic Acid active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Retinoic Acid active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-640-2015·2015-04-29

    Attix Pharmaceuticals Recalls Doxorubicin HCI Due to Penicillin Cross Contamination Risk

    Attix Pharmaceuticals is recalling Doxorubicin HCI active pharmaceutical ingredient due to potential penicillin cross-contamination from repackaging in a shared facility.

    Product
    Doxorubicin HCI active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-599-2015·2015-04-29

    Attix Pharmaceuticals Recalls Colchicine API Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling colchicine active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging. The product was distributed to compounding pharmacies and research organizations.

    Product
    Colchicine active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-552-2015·2015-04-29

    Attix Pharmaceuticals Recalls Bupivacaine HCl Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Bupivacaine HCl active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Bupivacaine HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-710-2015·2015-04-29

    Attix Pharmaceuticals Recalls Hyaluronic Acid Sodium Salt Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Hyaluronic Acid Sodium Salt (Pharma Grade) active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Hyaluronic Acid Sodium Salt (Pharma Grade) active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-559-2015·2015-04-29

    Attix Pharmaceuticals Recalls Capecitabine Due to Penicillin Cross Contamination

    Attix Pharmaceuticals is recalling capecitabine active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Capecitabine active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-654-2015·2015-04-29

    Attix Pharmaceuticals Recalls Estradiol Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Estradiol (Non-Micronized) active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Estradiol (Non-Micronized) active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-897-2015·2015-04-29

    Attix Pharmaceuticals Recalls Sodium Dichloroacetate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Sodium Dichloroacetate active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Sodium Dichloroacetate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-800-2015·2015-04-29

    Attix Pharmaceuticals Recalls Minoxidil API Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Minoxidil active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Minoxidil active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-708-2015·2015-04-29

    Attix Pharmaceuticals Recalls Hyaluronic Acid Sodium Salt Injection Grade API

    Attix Pharmaceuticals is recalling Hyaluronic Acid Sodium Salt (Injection Grade) active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Hyaluronic Acid Sodium Salt (Injection Grade) active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-518-2015·2015-04-29

    Attix Pharmaceuticals Recalls Amlodipine Besylate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling amlodipine besylate active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Amlodipine besylate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-625-2015·2015-04-29

    Attix Pharmaceuticals Recalls Dexchlorpheniramine Maleate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Dexchlorpheniramine Maleate active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Dexchlorpheniramine Maleate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-831-2015·2015-04-29

    Attix Pharmaceuticals Recalls Pantoprazole Sodium Monohydrate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling all lots of Pantoprazole Sodium Monohydrate repackaged between January 2012 and February 2015 due to potential penicillin cross-contamination.

    Product
    Pantoprazole Sodium Monohydrate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-557-2015·2015-04-29

    Attix Pharmaceuticals Recalls Calcium Sulfate Hemihydrate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Calcium Sulfate Hemihydrate active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Calcium Sulfate Hemihydrate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-653-2015·2015-04-29

    Attix Pharmaceuticals Recalls Estradiol Due to Penicillin Cross Contamination Risk

    Attix Pharmaceuticals is recalling Estradiol (Micronized) active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Estradiol (Micronized) active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-755-2015·2015-04-29

    Attix Pharmaceuticals Recalls Levocetirizine Dihydrochloride Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Levocetirizine Dihydrochloride active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Levocetirizine Dihydrochloride active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-596-2015·2015-04-29

    Attix Pharmaceuticals Recalls Clonidine HCl Due to Penicillin Cross Contamination Risk

    Attix Pharmaceuticals is recalling Clonidine HCl active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Clonidine HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-733-2015·2015-04-29

    Attix Pharmaceuticals Recalls Indomethacin Sodium Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Indomethacin Sodium active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Indomethacin Sodium active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-709-2015·2015-04-29

    Attix Pharmaceuticals Recalls Hyaluronic Acid Sodium Salt Due to Penicillin Cross-Contamination

    Attix Pharmaceuticals is recalling Hyaluronic Acid Sodium Salt (Ophthalmic Grade) because it was repackaged in a facility with penicillin products, posing a cross-contamination risk.

    Product
    Hyaluronic Acid Sodium Salt (Ophthalmic Grade) active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-606-2015·2015-04-29

    Cyclophosphamide Monohydrate Recalled for Potential Penicillin Cross Contamination

    Attix Pharmaceuticals is recalling Cyclophosphamide Monohydrate active pharmaceutical ingredient due to potential penicillin cross contamination during repackaging.

    Product
    Cyclophosphamide Monohydrate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-742-2015·2015-04-29

    Attix Pharmaceuticals Recalls Ketoprofen Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling ketoprofen active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Ketoprofen active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-873-2015·2015-04-29

    Attix Pharmaceuticals Recalls Quetiapine Fumarate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Quetiapine Fumarate active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Quetiapine Fumarate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-500-2015·2015-04-29

    Attix Pharmaceuticals Recalls Acetylsalicyclic Acid Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling acetylsalicyclic acid active pharmaceutical ingredient due to potential penicillin cross-contamination. The product was distributed to compounding pharmacies and research organizations.

    Product
    Acetylsalicyclic acid active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-814-2015·2015-04-29

    Attix Pharmaceuticals Recalls Natamycin API Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Natamycin active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging. The recall affects lots distributed nationwide to compounding pharmacies and research organizations.

    Product
    Natamycin active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-493-2015·2015-04-29

    Attix Pharmaceuticals Recalls 2-Deoxy-D-Glucose Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling 2-Deoxy-D-Glucose active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    2-Deoxy-D-Glucose active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, On
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-898-2015·2015-04-29

    Attix Pharmaceuticals Recalls Sodium Gluconate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Sodium Gluconate active pharmaceutical ingredient due to potential penicillin cross-contamination from repackaging in a shared facility.

    Product
    Sodium Gluconate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-748-2015·2015-04-29

    Attix Pharmaceuticals Recalls Lansoprazole Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling all lots of lansoprazole active pharmaceutical ingredient distributed between January 5, 2012, and February 12, 2015, due to potential penicillin cross-contamination.

    Product
    Lansoprazole active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-827-2015·2015-04-29

    Attix Pharmaceuticals Recalls Oseltamivir Phosphate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Oseltamivir Phosphate active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Oseltamivir Phosphate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-804-2015·2015-04-29

    Mitotane API Recalled for Potential Penicillin Cross-Contamination

    Attix Pharmaceuticals is recalling Mitotane active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Mitotane active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-661-2015·2015-04-29

    Attix Pharmaceuticals Recalls Ethinyl Estradiol Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling all lots of Ethinyl Estradiol active pharmaceutical ingredient distributed between January 5, 2012, and February 12, 2015, due to potential penicillin cross-contamination.

    Product
    Ethinyl Estradiol active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-870-2015·2015-04-29

    Attix Pharmaceuticals Recalls Proparacaine HCl Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Proparacaine HCl active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Proparacaine HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-491-2015·2015-04-29

    Attix Pharmaceuticals Recalls 5-Aminolevulinic Acid Hydrochloride Due to Penicillin Cross-Contamination

    Attix Pharmaceuticals is recalling 5-Aminolevulinic Acid Hydrochloride active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    5-Aminolevulinic Acid Hydrochloride active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-562-2015·2015-04-29

    Attix Pharmaceuticals Recalls Carboplatin Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Carboplatin active pharmaceutical ingredient repackaged between January 2012 and February 2015 due to potential penicillin cross-contamination.

    Product
    Carboplatin active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-663-2015·2015-04-29

    Attix Pharmaceuticals Recalls Etidronate Disodium Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Etidronate Disodium active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Etidronate Disodium active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-701-2015·2015-04-29

    Attix Pharmaceuticals Recalls Guanabenz Acetate Due to Penicillin Cross Contamination

    Attix Pharmaceuticals is recalling Guanabenz Acetate active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Guanabenz Acetate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-553-2015·2015-04-29

    Attix Pharmaceuticals Recalls Bupropion HCI Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Bupropion HCI active pharmaceutical ingredient due to potential penicillin cross-contamination from repackaging in a shared facility.

    Product
    Bupropion HCI active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-766-2015·2015-04-29

    Attix Pharmaceuticals Recalls Lisinopril Due to Penicillin Cross Contamination Risk

    Attix Pharmaceuticals is recalling Lisinopril active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Lisinopril active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-917-2015·2015-04-29

    Attix Pharmaceuticals Recalls Telaprevir API Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Telaprevir active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Telaprevir active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-825-2015·2015-04-29

    Attix Pharmaceuticals Recalls Ondansetron HCl Dihydrate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Ondansetron HCl Dihydrate active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Ondansetron HCl Dihydrate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-647-2015·2015-04-29

    Attix Pharmaceuticals Recalls EDTA Dipotassium Magnesium Salt Dihydrate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling EDTA Dipotassium Magnesium Salt Dihydrate active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    EDTA Dipotassium Magnesium Salt Dihydrate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-775-2015·2015-04-29

    Attix Pharmaceuticals Recalls Mefloquine HCl Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Mefloquine HCl active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Mefloquine HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-745-2015·2015-04-29

    Attix Pharmaceuticals Recalls L-Asparaginase Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling L-Asparaginase active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    L-Asparaginase active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-951-2015·2015-04-29

    Attix Pharmaceuticals Recalls Vecuronium Bromide Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Vecuronium Bromide active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Vecuronium Bromide active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-612-2015·2015-04-29

    Attix Pharmaceuticals Recalls Dantrolene Sodium Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Dantrolene Sodium active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Dantrolene Sodium (Orange) active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-743-2015·2015-04-29

    Attix Pharmaceuticals Recalls Ketorolac Tromethamine Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling all lots of Ketorolac Tromethamine active pharmaceutical ingredient distributed between January 5, 2012, and February 12, 2015, due to potential penicillin cross-contamination.

    Product
    Ketorolac Tromethamine active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-508-2015·2015-04-29

    Alpha Chymotrypsin Recalled for Potential Penicillin Cross Contamination

    Attix Pharmaceuticals is recalling Alpha Chymotrypsin active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Alpha Chymotrypsin active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-850-2015·2015-04-29

    Attix Pharmaceuticals Recalls Potassium Chloride Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling all lots of Potassium Chloride active pharmaceutical ingredient distributed between January 5, 2012, and February 12, 2015, due to potential penicillin cross-contamination.

    Product
    Potassium Chloride active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-576-2015·2015-04-29

    Attix Pharmaceuticals Recalls Chloramphenicol Palmitate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Chloramphenicol Palmitate active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Chloramphenicol Palmitate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-573-2015·2015-04-29

    Attix Pharmaceuticals Recalls Cetirizine HCI Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Cetirizine HCI active pharmaceutical ingredient due to potential penicillin cross-contamination. The product was distributed to compounding pharmacies and research organizations.

    Product
    Cetirizine HCI active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-611-2015·2015-04-29

    Attix Pharmaceuticals Recalls Dantrolene Sodium Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Dantrolene Sodium API lots distributed between January 2012 and February 2015 due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Dantrolene Sodium (Light Yellow) active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-527-2015·2015-04-29

    Attix Pharmaceuticals Recalls Atomoxetine HCl Due to Penicillin Cross Contamination Risk

    Attix Pharmaceuticals is recalling Atomoxetine HCl active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Atomoxetine HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-817-2015·2015-04-29

    Attix Pharmaceuticals Recalls Nilotinib API Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Nilotinib active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Nilotinib active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-912-2015·2015-04-29

    Attix Pharmaceuticals Recalls Tadalafil Citrate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Tadalafil Citrate active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Tadalafil Citrate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-892-2015·2015-04-29

    Attix Pharmaceuticals Recalls Sevelamer HCl Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Sevelamer HCl active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Sevelamer HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-510-2015·2015-04-29

    Attix Pharmaceuticals Recalls Ambroxol HCl Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Ambroxol HCl active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Ambroxol HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-864-2015·2015-04-29

    Attix Pharmaceuticals Recalls Procaine HCl Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Procaine HCl active pharmaceutical ingredient due to potential penicillin cross-contamination. The product was distributed to compounding pharmacies and research organizations.

    Product
    Procaine HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-957-2015·2015-04-29

    Attix Pharmaceuticals Recalls Zinc Pyrithione Due to Penicillin Cross Contamination Risk

    Attix Pharmaceuticals is recalling Zinc Pyrithione active pharmaceutical ingredient due to potential penicillin cross-contamination from repackaging in a shared facility.

    Product
    Zinc Pyrithione active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-511-2015·2015-04-29

    Attix Pharmaceuticals Recalls Amikacin Sulfate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Amikacin Sulfate active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Amikacin Sulfate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-926-2015·2015-04-29

    Attix Pharmaceuticals Recalls Thimerosal Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Thimerosal active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Thimerosal active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-737-2015·2015-04-29

    Attix Pharmaceuticals Recalls Isosorbide Dinitrate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Isosorbide Dinitrate active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Isosorbide Dinitrate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-0490-2015·2015-04-29

    Hospira Recalls Sodium Chloride Injection Due to Sterility Concerns

    Hospira Inc. is recalling 128,050 units of 0.9% Sodium Chloride Injection due to a potential leak at the administrative port that compromises sterility.

    Product
    SODIUM CHLORIDE — SODIUM CHLORIDE (SODIUM CHLORIDE)
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereUSDA FSIS·071-2015·2015-04-29

    Golden Krust Patties Recalls Beef and Chicken Products for Undeclared Egg

    Golden Krust Patties is recalling approximately 9 million pounds of beef and chicken products because they contain egg, a known allergen, that is not declared on the label.

    Product
    Golden Krust Patties Inc. — Golden Krust Patties Recalls Beef and Chicken Products Due To Misbranding and Undeclared Allergens
    Category
    Food
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-773-2015·2015-04-29

    Attix Pharmaceuticals Recalls Mechlorethamine HCl Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Mechlorethamine HCl active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Mechlorethamine HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-799-2015·2015-04-29

    Attix Pharmaceuticals Recalls Minocycline HCl Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Minocycline HCl active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Minocycline HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-600-2015·2015-04-29

    Attix Pharmaceuticals Recalls Cortisone Acetate Micronized Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Cortisone Acetate Micronized active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Cortisone Acetate Micronized active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-952-2015·2015-04-29

    Attix Pharmaceuticals Recalls Venlafaxine HCl Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Venlafaxine HCl active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Venlafaxine HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-783-2015·2015-04-29

    Attix Pharmaceuticals Recalls Methazolamide Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Methazolamide active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Methazolamide active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-536-2015·2015-04-29

    Attix Pharmaceuticals Recalls Benazepril API Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Benazepril active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Benazepril active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-830-2015·2015-04-29

    Attix Pharmaceuticals Recalls Pancuronium Bromide Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Pancuronium Bromide active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Pancuronium Bromide active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-920-2015·2015-04-29

    Terbinafine Base Recalled for Potential Penicillin Cross Contamination

    Attix Pharmaceuticals is recalling Terbinafine Base active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Terbinafine Base active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-843-2015·2015-04-29

    Pioglitazone HCl Recalled for Potential Penicillin Cross Contamination

    Attix Pharmaceuticals is recalling Pioglitazone HCl active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Pioglitazone HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-681-2015·2015-04-29

    Attix Pharmaceuticals Recalls Flunarizine HCl Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Flunarizine HCl active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Flunarizine HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-563-2015·2015-04-29

    Attix Pharmaceuticals Recalls Carboxymethyl Cellulose Sodium Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Carboxymethyl Cellulose Sodium active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Carboxymethyl Cellulose Sodium active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-945-2015·2015-04-29

    Attix Pharmaceuticals Recalls Trimeprazine Tartrate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Trimeprazine Tartrate active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Trimeprazine Tartrate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-687-2015·2015-04-29

    Attix Pharmaceuticals Recalls Fluprostenol Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Fluprostenol active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Fluprostenol active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-635-2015·2015-04-29

    Attix Pharmaceuticals Recalls Dobutamine Hydrochloride Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Dobutamine Hydrochloride active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Dobutamine Hydrochloride active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-702-2015·2015-04-29

    Halobetasol Propionate Recalled for Potential Penicillin Cross Contamination

    Attix Pharmaceuticals is recalling Halobetasol Propionate active ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Halobetasol Propionate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-646-2015·2015-04-29

    Attix Pharmaceuticals Recalls Duloxetine HCl Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Duloxetine HCl active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Duloxetine HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-818-2015·2015-04-29

    Attix Pharmaceuticals Recalls Nitazoxanide Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Nitazoxanide active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Nitazoxanide active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-700-2015·2015-04-29

    Glipizide API Recalled for Potential Penicillin Cross-Contamination

    Attix Pharmaceuticals is recalling Glipizide active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Glipizide active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-815-2015·2015-04-29

    Attix Pharmaceuticals Recalls Neostigmine Methylsulfate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Neostigmine Methylsulfate active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Neostigmine Methylsulfate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-908-2015·2015-04-29

    Attix Pharmaceuticals Recalls Sulfisoxazole Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Sulfisoxazole active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Sulphafurazole (Sulfisoxazole) active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-948-2015·2015-04-29

    Valacyclovir HCl Recalled for Potential Penicillin Cross Contamination

    Attix Pharmaceuticals is recalling Valacyclovir HCl active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Valacyclovir HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-853-2015·2015-04-29

    Attix Pharmaceuticals Recalls Pralidoxime Chloride Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Pralidoxime Chloride active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Pralidoxime Chloride active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-617-2015·2015-04-29

    Attix Pharmaceuticals Recalls Dasatinib API Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Dasatinib active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Dasatinib active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereNHTSA·15V255000·2015-04-29

    Triumph Recalls 2014-2015 Motorcycles for Rear Shock Absorber Defect

    Triumph is recalling 566 model year 2014-2015 Daytona 675 R and Speed Triple R motorcycles because a rear shock absorber nut may loosen, potentially causing loss of vehicle control.

    Product
    TRIUMPH — TRIUMPH DAYTONA 675 R, SPEED TRIPLE R ABS A1, DAYTONA 675 R ABS B1, SPEED TRIPLE R
    Category
    Vehicle
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-882-2015·2015-04-29

    Attix Pharmaceuticals Recalls Rivaroxaban API Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Rivaroxaban active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Rivaroxaban active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-497-2015·2015-04-29

    Attix Pharmaceuticals Recalls 5-Fluorouracil Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling 5-Fluorouracil active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    5-Fluorouracil active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-867-2015·2015-04-29

    Progesterone API Recalled for Potential Penicillin Cross Contamination

    Attix Pharmaceuticals is recalling progesterone active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Progesterone active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-604-2015·2015-04-29

    Attix Pharmaceuticals Recalls Cyanocobalamin Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling cyanocobalamin active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Cyanocobalamin active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide

Looking for a different month? Back to 2015.